Sandoz Announces Acquisition of Evotec’s Just - Evotec Biologics EU SAS

Sandoz, a leading global generics and biosimilars company, has acquired Evotec’s Just - Evotec Biologics EU SAS for an undisclosed amount.

This transaction represents a direct corporate acquisition, transferring the full ownership and operational control of the specialized biologics entity from Evotec to Sandoz.

Just - Evotec Biologics EU SAS operates a facility dedicated to the development and manufacturing of biological medicines.

The acquisition is strategically significant for Sandoz as it seeks to deepen its capabilities within the rapidly expanding biologics market.

This move allows Sandoz to enhance its internal capacity for the intricate development and high-quality production of biosimilars and other complex biological medicines, which are central to its future growth strategy.

By securing dedicated biologics manufacturing assets, Sandoz aims to reduce reliance on third-party manufacturing and gain greater control over its supply chain for these critical products.

Expected synergies from this acquisition encompass significant operational efficiencies and a notable expansion of Sandoz's manufacturing footprint.

The integration of Just - Evotec Biologics EU SAS’s specialized technological expertise and modern infrastructure is anticipated to accelerate Sandoz’s timelines for bringing new biologic products to market.

Furthermore, it is expected to optimize its overall production processes and enhance the company's ability to scale manufacturing in response to market demands.

This strategic alignment is designed to create a more robust and vertically integrated biopharmaceutical offering, positioning Sandoz to better serve global healthcare needs.

The combined entity is poised to leverage these expanded capabilities to address the increasing worldwide demand for affordable and accessible biologics, particularly in therapeutic areas with high unmet needs.

This acquisition underscores Sandoz’s commitment to advancing its biosimilar pipeline and reinforcing its competitive position as a key player in the evolving biopharmaceutical industry.